AP
THC icon

Antipodes Partners’s Tenet Healthcare THC Stock Holding History

Antipodes Partners’s Portfolio THC Stock Details THC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Buy
+203
New +$37.3K ﹤0.01% 118

Other funds holding THC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Antipodes Partners's THC Position: Q2 2026 in Review

Antipodes Partners opened a new position in Tenet Healthcare (THC) in Q2 2026: 203 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #118 among its holdings.

673 funds tracked by Wall St. Rank hold THC as of Q2 2026.

  • Antipodes Partners held 203 shares of Tenet Healthcare worth $38K as of Q2 2026.
  • Tenet Healthcare was a new Antipodes Partners position in Q2 2026.
  • Tenet Healthcare made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #118 holding.
  • 673 funds tracked by Wall St. Rank held Tenet Healthcare as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.